AEON

AEON Biopharma, Inc. (AEON) | Rumor.io

AEON Biopharma

AEON

Attention (50-day avg)0%

Attention rank (50-day avg)#1,639

Bullish sentiment (50-day avg)89%

Price to earnings ratio0.33

Market capitalization13.1M

Earnings per share-4.52

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-39.2M

Social

What share of all stock conversation is about AEON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 14

AEON Biopharma announced positive pilot forced-degradation results on Sept. 9, showing ABP-450 and Botox had comparable degradation behavior under thermal and oxidative stress.
The company plans a formal multi-lot comparability study next, which is considered new scientific/comparability data, not just a promotional announcement.
Insiders hold a high 53% of AEON shares and have not sold any in the past 3 years, with one insider buying 1,150,000 shares less than a month ago.

Generated by AI

Sentiment

Of the messages about AEON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.74% -2.92	82.39% +3.94
Bearish	—	—	11.26% +2.92	17.61% -3.94

Bullish· Sep 10

The company has achieved a significant scientific breakthrough, with a pilot degradation study demonstrating the molecular and analytical equivalence of its biosimilar, ABP-450, to BOTOX®.
The study's results, released on September 9, 2026, virtually eliminate the company's greatest scientific risk – potential biological dissimilarity to the original BOTOX® product.
The stock is experiencing a strong price trend, with a 19.53% overnight increase in the US session, indicating a strengthening price trend and potential for further growth.

Bearish· Mar 13

$AEON's price drop from $5 to $0.56 is a significant decline, indicating a loss of investor confidence.
The company's stock price is not warranted by its current performance, suggesting a disconnect between the market's perception and the company's fundamentals.
$AEON's dilution and warrants floor price at $1 may lead to further price drops as investors sell their shares to realize profits.

Generated by AI

Topics

Of the messages about AEON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	73.68%	50.42%
Technical Analysis	—	0%	19.3%	18.33%
Analysts	—	0%	7.02%	15.83%
Controversies	—	0%	0%	0.42%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	15%

Sep 10

AEON Biopharma announces highly successful pilot stability data, confirming a molecular structure identical to BOTOX®, virtually eliminating the company's greatest scientific risk.
The study demonstrates stability and oxidation patterns comparable to the original BOTOX®, substantiating the molecular and analytical equivalence of AEON's biosimilar, ABP-450.
AEON Biopharma is presenting live at the Lake Street BIG10 Conference in New York, backed by sensational laboratory data that demonstrates its blockbuster candidate, ABP-450, is in no way inferior to the multi-billion-dollar original, BOTOX.

Generated by AI

Community

Of the messages about AEON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	6.25%	24.82%
Newcomers	—	100%	93.75%	75.18%

Regulars· Sep 10

$AEON holding a good range, indicating a positive sentiment from regulars.
Market respect is being shown to $AEON, suggesting a growing interest in the stock.
Regulars are keeping a strong watch on $AEON, implying a high level of attention and focus on the asset.

Newcomers· Sep 14

The company has announced positive pilot forced-degradation results on Sept. 9, showing ABP-450 and Botox had comparable degradation behavior under thermal and oxidative stress.
A formal multi-lot comparability study is planned next, indicating the company is taking a scientific approach to demonstrate the comparability of its product.
Insiders have been buying shares, with one insider purchasing 1,150,000 shares less than a month ago, and no insiders selling in the past 3 years, with insiders holding a high 53% of the shares.

Generated by AI

News

Also Discussed

Investors talking about AEON also mention

#	Name	Attention
1	WRNT - Warrantee Inc. American Depositary Shares	——
2	noco-noco Inc.NCNC	0%0
3	Ocean Biomedical Inc.OCEA	0%0
4	GlucoTrack Inc.GCTK	0%0
5	Cheetah Net Supply Chain Service Inc.CTNT	0.02%-0.01
6	Chanson International Holding Class A Ordinary SharesCHSN	0%0
7	FOXO - FOXO Technologies Inc.	——
8	MOND - Mondee Holdings, Inc.	——
9	VHNA - Vahanna Tech Edge Acquisition I Corp.	——
10	CRGX - CARGO Therapeutics, Inc. Common Stock	——

AEON Biopharma, Inc.

Healthcare
Biotechnology

Aeon Biopharma, Inc. Class A Common Stock represents the equity of Aeon Biopharma, Inc., a biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic use. The company’s current work centers on ABP-450 (prabotulinumtoxinA), a botulinum toxin product candidate being studied for medical conditions such as cervical dystonia and migraine. Its business is concentrated on advancing injectable treatments for debilitating disorders and building a portfolio around toxin-based therapeutics. Aeon Biopharma operates in the healthcare and biotechnology sectors, where it plays the role of a specialized clinical-stage developer working to expand treatment options in neurology and related therapeutic areas. Based in Irvine, California, the company’s Class A common stock provides public market exposure to its ongoing research, development, and commercialization efforts in the biopharmaceutical market.

Website

Location

5 Park Plaza

Irvine, CA, 92614

United States

Social

What share of all stock conversation is about AEON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 14

AEON Biopharma announced positive pilot forced-degradation results on Sept. 9, showing ABP-450 and Botox had comparable degradation behavior under thermal and oxidative stress.
The company plans a formal multi-lot comparability study next, which is considered new scientific/comparability data, not just a promotional announcement.
Insiders hold a high 53% of AEON shares and have not sold any in the past 3 years, with one insider buying 1,150,000 shares less than a month ago.

Generated by AI

Sentiment

Of the messages about AEON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.74% -2.92	82.39% +3.94
Bearish	—	—	11.26% +2.92	17.61% -3.94

Bullish· Sep 10

The company has achieved a significant scientific breakthrough, with a pilot degradation study demonstrating the molecular and analytical equivalence of its biosimilar, ABP-450, to BOTOX®.
The study's results, released on September 9, 2026, virtually eliminate the company's greatest scientific risk – potential biological dissimilarity to the original BOTOX® product.
The stock is experiencing a strong price trend, with a 19.53% overnight increase in the US session, indicating a strengthening price trend and potential for further growth.

Bearish· Mar 13

$AEON's price drop from $5 to $0.56 is a significant decline, indicating a loss of investor confidence.
The company's stock price is not warranted by its current performance, suggesting a disconnect between the market's perception and the company's fundamentals.
$AEON's dilution and warrants floor price at $1 may lead to further price drops as investors sell their shares to realize profits.

Generated by AI

Topics

Of the messages about AEON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	73.68%	50.42%
Technical Analysis	—	0%	19.3%	18.33%
Analysts	—	0%	7.02%	15.83%
Controversies	—	0%	0%	0.42%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	15%

Sep 10

AEON Biopharma announces highly successful pilot stability data, confirming a molecular structure identical to BOTOX®, virtually eliminating the company's greatest scientific risk.
The study demonstrates stability and oxidation patterns comparable to the original BOTOX®, substantiating the molecular and analytical equivalence of AEON's biosimilar, ABP-450.
AEON Biopharma is presenting live at the Lake Street BIG10 Conference in New York, backed by sensational laboratory data that demonstrates its blockbuster candidate, ABP-450, is in no way inferior to the multi-billion-dollar original, BOTOX.

Generated by AI

Community

Of the messages about AEON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	6.25%	24.82%
Newcomers	—	100%	93.75%	75.18%

Regulars· Sep 10

$AEON holding a good range, indicating a positive sentiment from regulars.
Market respect is being shown to $AEON, suggesting a growing interest in the stock.
Regulars are keeping a strong watch on $AEON, implying a high level of attention and focus on the asset.

Newcomers· Sep 14

The company has announced positive pilot forced-degradation results on Sept. 9, showing ABP-450 and Botox had comparable degradation behavior under thermal and oxidative stress.
A formal multi-lot comparability study is planned next, indicating the company is taking a scientific approach to demonstrate the comparability of its product.
Insiders have been buying shares, with one insider purchasing 1,150,000 shares less than a month ago, and no insiders selling in the past 3 years, with insiders holding a high 53% of the shares.

Generated by AI

AEON Biopharma

Social

Sep 14

Bullish· Sep 10

Bearish· Mar 13

Sep 10

Regulars· Sep 10

Newcomers· Sep 14

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Laidlaw initiates Aeon Biopharma stock coverage with buy rating

AEON Biopharma names Paul Lee as acting chief regulatory officer

Also Discussed

AEON Biopharma, Inc.

Company Information

Location

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Laidlaw initiates Aeon Biopharma stock coverage with buy rating

AEON Biopharma names Paul Lee as acting chief regulatory officer

Also Discussed

Social

Sep 14

Bullish· Sep 10

Bearish· Mar 13

Sep 10

Regulars· Sep 10

Newcomers· Sep 14